Risk of dementia in patients taking beta blocker as antihypertensive treatment: a cross sectional study
DOI:
https://doi.org/10.18203/2349-3933.ijam20195580Keywords:
Atenolol, Beta blockers, Bisoprolol, Carvedilol, Cognition, Dementia, HypertensionAbstract
Background: Hypertension is considered to be the third most important disease in the list of diseases in the south Asian region. Several trials have shown active treatment of hypertension reduced the incidence of dementia. This study was adopted to understand the cognitive status of patients using beta blockers for hypertension for a period of more than 5 years.
Methods: The study was done during the period of August 2018 and September 2018. Patients taking beta blockers for atleast 5 years were included and was made to take the MMSE test which is scored out of 30 marks containing 11 questions, each of varying marks.
Results: In the study, 54 patients were included, 8 out of 54 patients taking beta blockers obtained a score of 30 which is 15% of the study population taking beta blockers, 15 out of 54 patients taking beta blockers obtained a score of 29 which corresponds to 28% of the study population, 21 out of 54 individuals taking beta blockers obtained a score of 28 which is 39% of the population taking it, 7 patients taking beta blockers obtained a score of 27 pertaining to 13% of the population. One patient obtained a score of 26 and two patients scored 25 out of 30. The average score obtained was 28.2963.
Conclusions: About 18.5% of the study population had scores below the average value of 28 in this study. This population is at higher risk of developing dementia in the future and need follow up.
References
Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-60.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005 Jan 15;365(9455):217-23.
Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens. 2004 Feb;18(2):73.
Anchala R, Kannuri NK, Pant H, Khan H, Franco OH, Di Angelantonio E, et al. Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. J Hypertens. 2014 Jun;32(6):1170-7.
Singh S, Shankar R, Singh GP. Prevalence and associated risk factors of hypertension: a cross-sectional study in urban Varanasi. Inter J Hypertens. 2017;2017.
Uludag A, Cevizci S, Uludag A. Epidemiology of Alzheimer's Disease with the Projection of Falls Among the Aged Population. Alzheimer's Dis: Challenges Future. 2015 Jul 1:1.
Podcasy JL, Epperson CN. Considering sex and gender in Alzheimer disease and other dementias. Dialogues Clini Neurosci. 2016 Dec;18(4):437.
Laurent S. Antihypertensive drugs. Pharmacol Res. 2017 Oct;124:116-125.
Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998 Oct 24;352(9137):1347-51.
in't Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM. Neurobiol Aging. 2001 May-Jun;22(3):407-12.
Hanon O, Forette F. Treatment of hypertension and prevention of dementia. Alzheimer's Dementia. 2005 Jul 1;1(1):30-7.
Tzourio C. Hypertension, cognitive decline, and dementia: an epidemiological perspective. Dialogues Clini Neurosci. 2007 Mar;9(1):61.
Ertekin A, Demir R, Özdemir G, Özel L, Özyıldırım E, Ulvi H. An investigation of the risk factors and prevalence of alzheimer’s disease in the eastern region of Turkey: A population based door-to-door survey. Europ J Gen Med. 2015 Jul 6;12(2):144-51.
Rouch L, Cestac P, Hanon O, Cool C, Helmer C, Bouhanick B, et al. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs. 2015 Feb 1;29(2):113-30.
Yi-Chun Kuana, Kuang-Wei Huang,Der-Jen Yen, Chaur-Jong Hu,Cheng-Li Ling, Chia-Hung Kao. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension. International Journal of Cardiology 220 (2016) 462–466.
Folstein MF, Folstein SE, McHugh PR. Mini-mental state: A practical method for grading the cognitivestate of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
Dening T, Sandilyan MB. Dementia: definitions and types. Nursing Standard (2014+). 2015 May 13;29(37):37.
